SCHEMBL385343

SCHEMBL385343

Cc1cc(C(=O)O)ccc1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.53
MAPK1 P28482 1/20 0.53
HTT P42858 1/20 0.53
RAB9A P51151 1/20 0.53
TSHR P16473 3/20 0.52
HSD17B10 Q99714 2/20 0.52
MYC P01106 1/20 0.52
ESR1 P03372 1/20 0.52
ALOX15 P16050 1/20 0.52
PTPN7 P35236 1/20 0.52
GRM1 Q13255 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
HTR7 P34969 2/20 0.50
MEN1 O00255 1/20 0.50
CYP1A2 P05177 1/20 0.50
KMT2A Q03164 1/20 0.50
ALDH1A1 P00352 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
PIM1 P11309 1/20 0.47
TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1478519 0.98 LMNA (0.52) LMNAMAPK1HTTRAB9ATSHR
SCHEMBL30462537 0.86 PIM1 (0.44) LMNAMAPK1HTTRAB9ATSHR
SCHEMBL4355959 0.84 SMN1; SMN2 (0.53) LMNAHTTTSHRTDP1CYP1A2
SCHEMBL1924482 0.83 PIM1 (0.47) LMNARAB9APIM1MAOAMAOB
SCHEMBL29602493 0.83 PIM1 (0.47) LMNARAB9APIM1MAOAMAOB
SCHEMBL503345 0.83 HDAC1 (0.63) LMNAMAPK1HTTRAB9ATSHR
Hydrochloric Acid SCHEMBL6563896 0.81 HDAC1 (0.61) LMNAMAPK1HTTRAB9ATSHR
Hydrogen Sulfide SCHEMBL29219504 0.81 PIM1 (0.46) HTTTDP1HTR7MEN1KMT2A
SCHEMBL580392 0.81 PARP1 (0.48) HSD17B10ALDH1A1SMN1; SMN2PIM1MAOA
SCHEMBL2098198 0.81 PIM1 (0.46) HTTTDP1HTR7KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119638770-A Clobetasol propionate derivative and preparation method thereof 复旦大学 2025-03-18 CN claimed
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 CN claimed
CN-116836081-A Ether epoxy toughening agent and preparation method and application thereof 中国林业科学研究院林产化学工业研究所 2023-10-03 CN claimed
EP-3551633-B1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2021-03-31 EP claimed
US-20260125359-A1 HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS FUJIAN HAIXI PHARMACEUTICALS CO LTD (CN) 2026-05-07 US disclosed
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-11-13 US disclosed
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2025-10-09 US disclosed
EP-4598923-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS The Regents of the University of California (US) 2025-08-13 EP disclosed
US-12378200-B2 Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (ACMSD) inhibitors ORSOBIO, INC. (US) 2025-08-05 US disclosed
US-20250145572-A1 Aminocarboxymuconate Semialdehyde Decarboxylase (ACMSD) Inhibitors ORSOBIO INC (US) 2025-05-08 US disclosed
EP-3976617-B1 FUSED HETEROCYCLIC DERIVATIVES JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2025-04-23 EP disclosed
EP-4536653-A2 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME Eisai R&D Management Co., Ltd. (JP) 2025-04-16 EP disclosed
WO-2001074811-A2 SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-10-11 WO disclosed
WO-2000063187-A1 FAB I INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2000-10-26 WO disclosed
US-6117866-A Bicyclic fibrinogen antagonists SMITHKLINE BEECHAM CORPORATION (US) 2000-09-12 US disclosed
CN-1259941-A new method ASTRA AB (SE) 2000-07-12 CN disclosed
EP-0738150-A4 BICYCLIC FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 1997-03-19 EP disclosed
EP-0738150-A1 BICYCLIC FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1996-10-23 EP disclosed
WO-1995018619-A1 BICYCLIC FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1995-07-13 WO disclosed
EP-0216127-A2 6-Phenoxymethyl-4-hydroxytetrahydropyran-2-ones, process for their preparation, their use as medicines, pharmaceutical compositions and intermediates HOECHST AKTIENGESELLSCHAFT (DE) 1987-04-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378200-B2 Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (ACMSD) inhibitors ALDH7A1, ACMSD, AMD1 LMNA 3970/4885MAPK1 4234/4885HTT 2837/4885
US-20250145572-A1 Aminocarboxymuconate Semialdehyde Decarboxylase (ACMSD) Inhibitors ACMSD, ALDH7A1, ALAD LMNA 3688/4885MAPK1 4182/4885HTT 2659/4885
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME NEU1, NEU2, NEU4 LMNA 1117/4885MAPK1 3114/4885HTT 558/4885
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C5, C1S, C9 LMNA 991/4885MAPK1 3329/4885HTT 602/4885
US-20260125359-A1 HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS ERBB2, ERBB3, ARRB1 LMNA 2496/4885MAPK1 80/4885HTT 4316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.